CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

January 8, 2025

Study Completion Date

January 8, 2025

Conditions
Undifferentiated Pleomorphic SarcomaMyxofibrosarcoma
Interventions
BIOLOGICAL

CAB-AXL-ADC

Conditionally active biologic anti-AXL antibody drug conjugate

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor

Trial Locations (40)

10032

Columbia University, New York

10065

Memorial Sloan Kettering, New York

14263

Roswell Park Cancer Institute, Buffalo

19104

The Children's Hospital of Philadelphia, Philadelphia

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

20010

Children's Research Institute, Washington D.C.

27157

Wake Forest Baptist Health, Winston-Salem

27710

Duke Cancer Institute, Durham

33612

Moffitt Cancer Center, Tampa

37203

Tennessee Oncology, Nashville

37232

Vanderbilt Ingram Cancer Center, Nashville

40202

Norton Cancer Institute, Louisville

43205

Nationwide Children's Hospital, Columbus

43210

The Ohio State University Wexner Medical Center, Columbus

44106

University Hospitals Seidman Cancer Center, Cleveland

45219

The Christ Hospital, Cincinnati

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

80218

Sarah Cannon Research Institute at Health One, Denver

84112

University of Utah - Huntsman Cancer Institute, Salt Lake City

85724

The University of Arizona Cancer Center, Tucson

89169

Comprehensive Cancer Center of Nevada, Las Vegas

90027

Children's Hospital Los Angeles, Los Angeles

90033

USC Norris Comprehensive Cancer Center, Los Angeles

90048

Tower Hematology Oncology Medical Group, Los Angeles

90212

Precision NextGen Oncology, Los Angeles

94158

UCSF Medical Center - Cancer Immunotherapy Clinic (CIC), San Francisco

97239

Oregon Health & Science University, Portland

98109

Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

National Cheng Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital, Taoyuan District

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioAtla, Inc.

INDUSTRY

NCT03425279 - CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | Biotech Hunter | Biotech Hunter